Lpath, Inc. (NASDAQ:LPTN) and Apollo Endosurgery, Inc.
Lpath, Inc. (NASDAQ:LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that the first cohort of six subjects has been dosed in the Phase 1 …
Lpath, Inc. (NASDAQ:LPTN) has been reiterated as a Buy at MLV by research analyst Arlinda Lee.
In a research report sent to investors today, MLV analyst Arlinda Lee reiterated a Buy rating on Lpath Inc (NASDAQ:LPTN) with a $11 price …